Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 3,370.00
+85.00 (2.59%)
At close: Sep 9, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 176.25 billion as of September 9, 2026. Its market cap has increased by 100.70% in one year.
Market Cap
176.25B
Enterprise Value
150.97B
Revenue
24.46B
Ranking
n/a
PE Ratio
n/a
Stock Price
3,370.00
ChartMarket Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 176.25B, an increase of 145.20%. That is a compound annual growth rate of 12.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 9, 2026 | 176.25B | -26.06% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| curacle co.,ltd. | 207.71B |
| Kangstem Biotech | 206.45B |
| Kanaph Therapeutics | 181.69B |
| NIBEC | 168.13B |
| Bio Solution | 165.15B |
| Ensol Biosciences | 144.77B |
| ISU Abxis | 138.84B |
| TiumBio | 136.98B |